Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review
IntroductionThe COVID-19 pandemic has delayed screening, diagnostic workup, and treatment in prostate cancer (PCa) patients. Our purpose was to review PCa screening, diagnostic workup, active surveillance (AS), radical prostatectomy (RP), radiotherapy (RT), androgen deprivation therapy (...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Société Internationale d’Urologie Journal |
| Subjects: | |
| Online Access: | https://siuj.org/index.php/siuj/article/view/130/50 |
| _version_ | 1797225298228412416 |
|---|---|
| author | Alan de J. Martinez-Salas Iñigo Navarro-Ruesga Erick A. Rodenas-Gil Jesus S. Muruato-Araiza Aldo Jimenez-García Irving Reyna-Blanco Jorge G. Morales-Montor Carlos Pacheco-Gahbler |
| author_facet | Alan de J. Martinez-Salas Iñigo Navarro-Ruesga Erick A. Rodenas-Gil Jesus S. Muruato-Araiza Aldo Jimenez-García Irving Reyna-Blanco Jorge G. Morales-Montor Carlos Pacheco-Gahbler |
| author_sort | Alan de J. Martinez-Salas |
| collection | DOAJ |
| description | IntroductionThe COVID-19 pandemic has delayed screening, diagnostic workup, and treatment in prostate cancer (PCa) patients. Our purpose was to review PCa screening, diagnostic workup, active surveillance (AS), radical prostatectomy (RP), radiotherapy (RT), androgen deprivation therapy (ADT) and systemic therapy during the COVID-19 pandemic.
Materials and MethodsWe performed a systematic literature search of MEDLINE, EMBASE, Scopus, LILACS, and Web of Science, according to Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA-P) statement for relevant material published from December 2019 to February 2021.
ResultsProstate biopsy can be delayed, except when high-risk PCa is suspected or the patient is symptomatic. Active surveillance is appropriate for patients with very low risk, low risk (LR) and favorable intermediate risk (FIR). RP and RT for high risk and very high risk can be safely postponed up to 3 months. Hypofractionated external beam RT (EBRT) is recommended when RT is employed. ADT should be used according to standard PCa-based indications. Chemotherapy should be postponed until the pandemic is contained.
ConclusionsThe international urological community was not prepared for such an acute and severe pandemic. PCa patients can be adequately managed according to risk stratification. During the COVID-19 pandemic, LR and FIR patients can be followed with active surveillance. Delaying RP and RT in high risk and locally advanced disease is justified. |
| first_indexed | 2024-03-08T18:03:31Z |
| format | Article |
| id | doaj.art-98437278a3724a8d9c1b0d19244365d9 |
| institution | Directory Open Access Journal |
| issn | 2563-6499 |
| language | English |
| last_indexed | 2024-04-24T14:06:47Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Société Internationale d’Urologie Journal |
| spelling | doaj.art-98437278a3724a8d9c1b0d19244365d92024-04-03T10:22:19ZengMDPI AGSociété Internationale d’Urologie Journal2563-64992021-07-012424025410.48083/MBSB4196Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic ReviewAlan de J. Martinez-SalasIñigo Navarro-RuesgaErick A. Rodenas-GilJesus S. Muruato-AraizaAldo Jimenez-GarcíaIrving Reyna-BlancoJorge G. Morales-MontorCarlos Pacheco-GahblerIntroductionThe COVID-19 pandemic has delayed screening, diagnostic workup, and treatment in prostate cancer (PCa) patients. Our purpose was to review PCa screening, diagnostic workup, active surveillance (AS), radical prostatectomy (RP), radiotherapy (RT), androgen deprivation therapy (ADT) and systemic therapy during the COVID-19 pandemic. Materials and MethodsWe performed a systematic literature search of MEDLINE, EMBASE, Scopus, LILACS, and Web of Science, according to Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols (PRISMA-P) statement for relevant material published from December 2019 to February 2021. ResultsProstate biopsy can be delayed, except when high-risk PCa is suspected or the patient is symptomatic. Active surveillance is appropriate for patients with very low risk, low risk (LR) and favorable intermediate risk (FIR). RP and RT for high risk and very high risk can be safely postponed up to 3 months. Hypofractionated external beam RT (EBRT) is recommended when RT is employed. ADT should be used according to standard PCa-based indications. Chemotherapy should be postponed until the pandemic is contained. ConclusionsThe international urological community was not prepared for such an acute and severe pandemic. PCa patients can be adequately managed according to risk stratification. During the COVID-19 pandemic, LR and FIR patients can be followed with active surveillance. Delaying RP and RT in high risk and locally advanced disease is justified.https://siuj.org/index.php/siuj/article/view/130/50androgen receptor antagonistsadjuvant chemotherapyprostatic neoplasmsradiotherapysars coronavirus |
| spellingShingle | Alan de J. Martinez-Salas Iñigo Navarro-Ruesga Erick A. Rodenas-Gil Jesus S. Muruato-Araiza Aldo Jimenez-García Irving Reyna-Blanco Jorge G. Morales-Montor Carlos Pacheco-Gahbler Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review Société Internationale d’Urologie Journal androgen receptor antagonists adjuvant chemotherapy prostatic neoplasms radiotherapy sars coronavirus |
| title | Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review |
| title_full | Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review |
| title_fullStr | Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review |
| title_full_unstemmed | Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review |
| title_short | Management Recommendations for Prostate Cancer During the COVID-19 Pandemic: A Systematic Review |
| title_sort | management recommendations for prostate cancer during the covid 19 pandemic a systematic review |
| topic | androgen receptor antagonists adjuvant chemotherapy prostatic neoplasms radiotherapy sars coronavirus |
| url | https://siuj.org/index.php/siuj/article/view/130/50 |
| work_keys_str_mv | AT alandejmartinezsalas managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview AT inigonavarroruesga managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview AT erickarodenasgil managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview AT jesussmuruatoaraiza managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview AT aldojimenezgarcia managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview AT irvingreynablanco managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview AT jorgegmoralesmontor managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview AT carlospachecogahbler managementrecommendationsforprostatecancerduringthecovid19pandemicasystematicreview |